AZD-6244: MEK1/2 inhibitor oncolytic

Drugs of the Future

Volumn 31, Issue 10, 2006, Pages 854-858

  Revill, P ^a   Serradell, N ^a   Bolos J ^a   Bozzo, J ^a  

^a NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROPHENYLAMINO) 4 FLUORO 1 METHYL 1 H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ARRY 142886; AZD 6244; CAPECITABINE; DOCETAXEL; GEFITINIB; GEMCITABINE; PEMETREXED; PROTEIN KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; FATIGUE; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; LUNG NON SMALL CELL CANCER; MELANOMA; NAUSEA; NONHUMAN; PANCREAS CANCER; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 33845992176     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.10.1040269     Document Type: Article

References (26)

1. Wallace, E.M., Lyssikatos, J.P., Hurley, B.T., Marlow, A.L. (Array BioPharma, Inc.). N3 alkylated benzimidazole derivatives as MEK inhibitors. EP 1482932, EP 1663210, JP 2005530709, US 2004116710, WO 03077914, WO 2005023251.
2. Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., Berman, K., Cobb, M.H. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 2001, 22(2): 153-83.
3. Herrera, R., Sebolt-Leopold, J.S. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002, 8(4, Suppl.): S27-31.
4. Kohno, M., Pouyssegur, J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 2006, 38(3): 200-11.
5. Staehler, M., Rohrmann, K., Haseke, N., Stief, G.G., Siebels, M. Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 2005, 6(7): 835-46.
6. Imajo, M., Tsuchiya, Y., Nishida, E. Regulatory mechanisms and functions of MAP kinase signaling pathways. IUBMB Life 2006, 58(5-6): 312-7.
7. Lewis, T.S., Hunt, J.B., Aveline, L.D. et al. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol Cell 2000, 6(6): 1343-54.
8. Lyssikatos, J., Yeh, T., Wallace, E. et al. ARRY-142886, a potent and selective MEK inhibitor: I) ATP-independent inhibition results in high enzymatic and cellular selectivity. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 3888.
9. Wallace, E., Yeh, T., Lyssikatos, J. et al. Preclinical development of ARRY-142886, a potent and selective MEK inhibitor. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 3891.
10. Lyssikatos, J. ARRY-142886 (AZD6244): Preclinical and early clinical development of a potent, selective MEK inhibitor. Proc Am Assoc Cancer Res (AACR) 2006, 47: Presentation April 3.
11. Koch, K. ARRY-142886, a novel and highly selective MEK inhibitor in clinical trials. Proc Am Assoc Cancer Res (AACR) 2004, 45: 1309.
12. Yeh, T., Wallace, E., Lyssikatos, J., Winkler, J. ARRY-142886, a potent and selective MEK inhibitor: II) Potency against cellular MEK leads to inhibition of cellular proliferation and induction of apoptosis in cell lines with mutant Ras or B-Raf. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 3889.
13. Zhou, Y., Benz, C. AZD6244 (ARRY-142886), a potent and selective MEK1/2 inhibitor, enhances tamoxifen sensitivity in resistant ER-positive/HER2-positive breast cancer cells with constitutively elevated MEK1/2. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 1344.
14. Lee, P., Wallace, E., Yeh, T. et al. Demonstration of broad in vivo anti-tumor activity of ARRY142886 (AZD6244), a potent and selective MEK inhibitor. Eur J Cancer - Suppl 2004, 2(8): Abst 368.
15. Lee, P., Wallace, E., Yeh, T. et al. ARRY-142886, a potent and selective MEK inhibitor: III) Efficacy in murine xenograft models correlates with decreased ERK phosphorylation. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 3890.
16. Tran, E., Chee Soo, K., Chow, P., Huynh, H. Targeted inhibition of the MEK-ERK signaling cascade by the selective MEK1/2 inhibitor AZD6244 (ARRAY-142886) for the treatment of hepatocellular carcinoma. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 5470.
17. Winkler, J., Lee, P., Wallace, E. et al. Anti-tumor activity, pharmacokinetic and pharmacodynamic effects of the MEK inhibitor ARRY-142886 (AZD6244) in a BxPC3 pancreatic tumor xenograft model. Eur J Cancer - Suppl 2004, 2(8): Abst 342.
18. Logie, A., Cockerill, M., Moore, S. et al. In vivo evaluation of pharmacodynamic biomarkers and mode of action of AZD6244 (ARRY142886). 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther 2005, Abst A240.
19. Cockerill, M., Logie, A., Speake, G. et al. Combination studies in vitro and in vivo with gefitinib (Iressa) and the MEK1/2 inhibitor AZD6244 (ARRY142886). 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther 2005, Abst A110.
20. Doyle, M., Yeh, T., Suzy, B. et al. Validation and use of a biomarker for clinical development of the MEK1/2 inhibitor ARRY-142886 (AZD6244). 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 3075.
21. Chow, L., Eckhardt, S., Reid, J. et al. A first in human dose-ranging study to assess the pharmacokinetics, pharmacodynamics, and toxicities of the MEK inhibitor, ARRY-142886 (AZD6244), in patients with advanced solid malignancies. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther 2005, Abst C162.
22. Array BioPharma receives phase 2 milestone payment from AstraZeneca. Array BioPharma Press Release September 14, 2006.
23. Randomised study to compare the efficacy of AZD6244 vs TMZ (NCT00338130). ClinicalTrials.gov Web site 2006.
24. AZD6244 versus pemetrexed (Alimta®) in patients with non-small cell lung cancer, who have failed one or two prior chemotherapy regimen (NCT00372788). ClinicalTrials.gov Web site 2006.
25. AZD6244 vs. capecitabine (Xeloda®) in patients with advanced or metastatic pancreatic cancer, who have failed first line gemcitabine therapy (NCT00372944). ClinicalTrials.gov Web site 2006.
26. Friday, B., Yu, C., Smith, P., Adjei, A. A potential role for modulation of a negative feedback loop between Erk and Raf in mediating sensitivity to the MEK inhibitor AZD6244 (ARRY-142886) in human lung cancer cell lines. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 4868.